Latest Observability News

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

OzAurum Resources has announced a significant new high-grade gold discovery at its Mulgabbie North Gold Project in Western Australia, revealing multiple shallow intercepts that could expand its existing resource base.

Nova Minerals' 2024 exploration at the RPM Regional area reveals high-grade gold samples, including a standout 52.3 g/t Au, highlighting significant resource potential at the Estelle Project in Alaska.

Cobre Limited reports promising assay results from diamond drilling at its Ngami Copper Project in Botswana, revealing significant copper and silver mineralization over a 4km strike. The findings bolster prospects for advancing the Comet target towards a formal resource estimate.

BMG Resources pushes forward with expansion drilling at its Abercromby and Bullabulling gold projects in Western Australia, supported by a recent $1.5 million capital raise. The company navigates regulatory caution by retracting prior production targets while maintaining a focus on resource growth.

X2M Connect reported a 51% revenue drop in Q2 FY25 as it shifts from hardware to SaaS, yet improved margins and EBITDA signal progress. Strategic partnerships in the Middle East and Taiwan offer promising growth avenues.

Surefire Resources NL advances its flagship Victory Bore project with a formal Expression of Interest from Germany’s HMS Bergbau, while new gold and copper targets emerge at the Yidby Project following recent drilling successes.

Altair Minerals has identified significant conductive and phase anomalies at its Olympic Domain Project, suggesting promising IOCG-style mineralisation near BHP’s Oak Dam deposit. The company plans advanced geophysical surveys to refine drill targets and accelerate exploration.

Alligator Energy reports significant progress across its uranium portfolio, including regulatory milestones at Samphire and promising drilling results at Big Lake and Nabarlek North, supported by a solid cash position of $20.2 million.

Ark Mines Ltd reported a significant cash outflow in its December 2024 quarter, prompting plans for a capital raising to support ongoing exploration activities.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

4DS Memory Limited reports successful testing of its 60nm memory cells and progresses toward 20nm technology, alongside a $6 million capital raise and a new design partnership with Infineon.